Exploring Therapeutic Strategies for HER2 Negative Breast Cancer: A Focus on Hormone Receptor Status
HER2-negative breast cancer represents a diverse set of conditions, each with its own clinical behavior and optimal management. For the majority of these tumors, which are also positive for the hormone receptors (HR+/HER2-), the core of the therapeutic plan involves hormone therapy. Medications are utilized to either block the hormone receptors on the cancer cells or to reduce the body's overall production of estrogen, effectively starving the tumor of the fuel it needs to grow. These endocrine agents are often administered for several years and have proven highly effective in reducing the risk of recurrence and improving long-term outcomes.
In addition to endocrine intervention, especially for larger or more aggressive hormone-sensitive tumors, other systemic treatments may be employed. For example, specific molecules that inhibit the cell cycle's progression, such as CDK4/6 inhibitors, have emerged as a way to enhance the effectiveness of hormone therapy, particularly in cases where the disease…